Analysis of structure-based virtual screening studies and characterization of identified active compounds.

Structure-based virtual screening makes explicit or implicit use of 3D target structure information to detect novel active compounds. Results of nearly 300 currently available original applications have been analyzed to characterize the state-of-the-art in this field. Compound selection from docking calculations is much influenced by subjective criteria. Although submicromolar compounds are identified, the majority of docking hits are only weakly potent. However, only a small percentage of docking hits can be reproduced by ligand-based methods. When docking calculations identify potent hits, they often originate from specialized compound sources (e.g., pharmaceutical compound decks or target-focused libraries) and also display a notable bias towards kinase targets. Structure-based virtual screening is the dominant approach to computational hit identification. Docking calculations frequently identify active compounds. Limited accuracy of compound scoring and ranking currently presents a major caveat of the approach that is often compensated for by chemical intuition and knowledge.

[1]  Jana Sopkova-de Oliveira Santos,et al.  Virtual Screening Discovery of New Acetylcholinesterase Inhibitors Issued from CERMN Chemical Library , 2010, J. Chem. Inf. Model..

[2]  Volodymyr G Bdzhola,et al.  Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. , 2006, Journal of medicinal chemistry.

[3]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[4]  Xin Chen,et al.  Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking , 2011, J. Chem. Inf. Model..

[5]  C. Bock,et al.  Discovery of novel types of inhibitors of S-adenosylmethionine synthesis by virtual screening. , 2009, Journal of medicinal chemistry.

[6]  A. Pierce,et al.  Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. , 2008, Journal of medicinal chemistry.

[7]  J. Bajorath,et al.  Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.

[8]  Megan L. Peach,et al.  Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. , 2009, Journal of medicinal chemistry.

[9]  W. Geldenhuys,et al.  Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. , 2010, Bioorganic & medicinal chemistry letters.

[10]  Robert P. Sheridan,et al.  Comparison of Topological, Shape, and Docking Methods in Virtual Screening. , 2007 .

[11]  György M. Keserü Structure-Based Virtual Screening , 2007 .

[12]  M. Mizutani,et al.  Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. , 2004, Journal of medicinal chemistry.

[13]  Angela Rao,et al.  Structure‐Based Pharmacophore Identification of New Chemical Scaffolds as Non‐Nucleoside Reverse Transcriptase Inhibitors. , 2007 .

[14]  Kyungik Lee,et al.  Structure-based virtual screening of Src kinase inhibitors. , 2009, Bioorganic & medicinal chemistry.

[15]  Jürgen Bajorath,et al.  Virtual compound screening in drug discovery. , 2012, Future medicinal chemistry.

[16]  David S. Wishart,et al.  Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors , 2009, Journal of medicinal chemistry.

[17]  J. Bajorath,et al.  State-of-the-art in ligand-based virtual screening. , 2011, Drug discovery today.

[18]  Victor A Kenyon,et al.  Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. , 2006, Journal of medicinal chemistry.

[19]  Thierry Langer,et al.  Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. , 2008, Journal of medicinal chemistry.

[20]  Scott A. Busby,et al.  A Combined Ligand‐ and Structure‐Based Virtual Screening Protocol Identifies Submicromolar PPARγ Partial Agonists , 2011, ChemMedChem.

[21]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[22]  Gisbert Schneider,et al.  Virtual screening and fast automated docking methods. , 2002, Drug discovery today.

[23]  Claudio N. Cavasotto,et al.  Homology modeling in drug discovery: current trends and applications. , 2009, Drug discovery today.

[24]  Alexander D. MacKerell,et al.  Identification and validation of human DNA ligase inhibitors using computer-aided drug design. , 2008, Journal of medicinal chemistry.

[25]  Alexander D. MacKerell,et al.  Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. , 2004, Journal of medicinal chemistry.

[26]  Ying Leng,et al.  Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling. , 2008, Bioorganic & medicinal chemistry letters.

[27]  O. El-Kabbani,et al.  Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening. , 2010, European journal of medicinal chemistry.

[28]  A. Leach,et al.  Prediction of Protein—Ligand Interactions. Docking and Scoring: Successes and Gaps , 2006 .

[29]  Richard A Bryce,et al.  In silico identification and biochemical characterization of novel inhibitors of NQO1. , 2006, Bioorganic & medicinal chemistry letters.

[30]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[31]  Waseem Ahmed,et al.  Identification of acridinyl hydrazides as potent aspartic protease inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[32]  R. Brinton,et al.  Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. , 2005, Journal of medicinal chemistry.

[33]  Steve Price,et al.  Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[34]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[35]  Alon Herschhorn,et al.  Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1. , 2008, Journal of medicinal chemistry.

[36]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[37]  W. Sippl,et al.  Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[38]  X. Barril,et al.  Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[39]  George W. A. Milne,et al.  Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. , 1996, Journal of medicinal chemistry.

[40]  Ruben Abagyan,et al.  Structure-Based Discovery of Novel Chemotypes for Adenosine A 2 A Receptor Antagonists , 2010 .

[41]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[42]  Hanna Geppert,et al.  Current Trends in Ligand-Based Virtual Screening: Molecular Representations, Data Mining Methods, New Application Areas, and Performance Evaluation , 2010, J. Chem. Inf. Model..

[43]  Weihua Li,et al.  Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening. , 2010, Journal of medicinal chemistry.

[44]  Kaixian Chen,et al.  Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase. , 2011, Bioorganic & medicinal chemistry letters.

[45]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[46]  Ying Leng,et al.  Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. , 2009, European journal of medicinal chemistry.

[47]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[48]  Dennis M. Krüger,et al.  Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.

[49]  Vladimir Sobolev,et al.  Target specific virtual screening: optimization of an estrogen receptor screening platform. , 2007, Journal of medicinal chemistry.

[50]  M. Drysdale,et al.  Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. , 2007, Bioorganic & medicinal chemistry letters.

[51]  M. Khanfar,et al.  Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. , 2010, Journal of medicinal chemistry.

[52]  Paul D Lyne,et al.  Structure-based virtual screening: an overview. , 2002, Drug discovery today.

[53]  Brian K Shoichet,et al.  Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.

[54]  Roy J. Vaz,et al.  Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. , 2010, Bioorganic & medicinal chemistry letters.

[55]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[56]  Zhili Zuo,et al.  Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening. , 2010, Bioorganic & medicinal chemistry letters.

[57]  Paolo Bonvini,et al.  Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. , 2006, Journal of medicinal chemistry.

[58]  Gerhard Klebe,et al.  Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. , 2003, Journal of medicinal chemistry.

[59]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[60]  J. Irwin,et al.  ZINC ? A Free Database of Commercially Available Compounds for Virtual Screening. , 2005 .

[61]  Markus H J Seifert,et al.  Targeted scoring functions for virtual screening. , 2009, Drug discovery today.

[62]  Maria A Miteva,et al.  Structure-based virtual ligand screening: recent success stories. , 2009, Combinatorial chemistry & high throughput screening.

[63]  Artem Cherkasov,et al.  An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin. , 2008, Journal of medicinal chemistry.

[64]  Kazuo Kuwata,et al.  Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. , 2010, Bioorganic & medicinal chemistry.

[65]  Giulio Rastelli,et al.  Structure-based design of potent aromatase inhibitors by high-throughput docking. , 2011, Journal of medicinal chemistry.